New combo therapy shows promise for Hard-to-Treat lung cancer brain metastases

This study tested a combination of three drugs—high-dose furmonertinib, bevacizumab, and pemetrexed given into the spinal fluid—in 46 people with a specific type of lung cancer (EGFR-mutated) that had spread to the lining of the brain (meningeal metastasis). The goal was to see if this treatment could delay tumor growth in the brain and improve survival. Participants received the drugs on a regular schedule, and researchers tracked how long the cancer stayed under control.